Edison Investment Research - Symbio Pharmaceuticals (4582) - New formulations extend Treakisym patent life

Report

Edison Investment Research

Dr Dennis Hulme

- New formulations extend Treakisym patent life

SymBio has substantially increased the value of its Treakisym franchise through in-licencing novel bendamustine formulations from Eagle Pharmaceuticals for $12.5m. The new formulations bring a lower cost of goods and 10 years of additional patent protection to help in life cycle management of the Treakisym franchise. Sales of Treakisym following the approval of two new indications in 2016 have exceeded the company’s expectations, leading it to upgrade FY17 sales guidance. Interim data from the global Phase III rigosertib trial could become available during Q417. We value SymBio at ¥19.7bn (unchanged), with the enhanced Treakisym portfolio offsetting the suspension of IONSYS development.

23/10/2017 10 EN

Underlying

Symbio Pharmaceuticals

Symbio Pharmaceuticals is a specialty biopharmaceutical company based in Japan. Co. specializes in the development and commercialization of drug candidates in oncology, hematology and autoimmunity areas. Co. has built pipelines (a group of newly developed drugs) with several pharmaceuticals, as well as, newly developed drugs in these disease areas. Co.'s product pipeline includes SyB L-0501(treatment of non-Hodgkin's lymphoma and mantle cell lymphoma); SyB L-1101/SyB C-1101, a multi-kinase inhibitor for the treatment of refractory/relapse myelodysplastic syndromes and solid tumor indications; and SyB D-0701, an antiemetic transdermal patch.

See profile

JP3383050006 Japan

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Dr Dennis Hulme

Other Reports on these Companies

Edison Investment Research

SymBio Pharmaceuticals - Termination of coverage

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH and Marshall Motor Holdings (MMH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

April 29, 2022 April 29, 2022 1 EN

Edison Investment Research

SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the product is being sold by SymBio directly, and it marks a substantial increase over prior sales trends. Sales have more than doubled since Q420 (¥0.6bn). Part of what is driving this is the early 2021 launch of the company’s ready-to-dilute (RTD) formulation. Moreover, SymBio recently expanded the indications approved for the drug to include diffuse large B-cell lymphoma (DLBCL), which may also drive future sales.

May 27, 2021 May 27, 2021 5 EN

Edison Investment Research

SymBio Pharmaceuticals - Treakisym approved for DLBCL

SymBio announced on 23 March 2021 that it has received marketing approval for Treakisym (bendamustine) for diffuse large B-cell lymphoma (DLBCL). The drug has been approved for relapsed and refractory disease in two combinations: with rituximab and polatuzumab vedotin or with rituximab alone. We expect this approval to approximately double the addressable market for the drug in Japan.

March 30, 2021 March 30, 2021 5 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

- New formulations extend Treakisym patent life

SymBio Pharmaceuticals - Termination of coverage

SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

SymBio Pharmaceuticals - Treakisym approved for DLBCL

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe